Blood Transfusion Diagnostic Market Insights: Rising Patient Pool with Chronic Ailments to Bolster Market Growth
The demand for blood transfusions has experienced an upsurge since the past several years. This is attributed to a large number of patients undergoing surgical procedures for various chronic diseases, such as aplastic anemia, sickle cell anemia and leukemia. This has prompted key players to focus on research & development for advanced instruments, assays and kits in blood banks and hospitals.
The recent COVID-19 pandemic has presented expansion opportunities for blood transfusion diagnostics market. A series of plasma transfusion trials are being conducted in the United States. Practitioners extract the liquid medium from recovered patients and introduce it to infected ones. This “convalescent plasma” is anticipated to boost the immunity of patients battling the disease. On the back of these trends, the global blood transfusion diagnostics market is poised to expand positively at a CAGR of 6.3% during the forecast period (2020-2025).
Application Insights: Molecular-based Disease Screening to Stimulate Market Growth
Molecular-based Disease Screening shall find widespread application of blood transfusion diagnostics, capturing over 70% of the market. This is due to rise in prevalence of Transfusion Transmitted Infections (TTIs) such as Hepatitis C & B and HIV-AIDS. Nucleic Acid Amplification Tests (NAT), based on molecular techniques, has revolutionized the blood diseases screening segment. The disease screening segment is poised to expand at a CAGR of 6.7% in the forecast period.
The blood grouping segment shall expand at a CAGR of 5.6% during the forecast period. Implementation of national blood transfusion policies on blood typing and greater affordability in terms of cost are anticipated to fuel growth. The blood grouping segment is poised to capture more than a quarter of the global blood transfusion diagnostics market in the forecast period.
To get detailed application insights on the blood transfusion diagnostics market, ask an analyst here
Regional Insights: North America Retains Hegemony, Asia-Pacific Presents Bankable Opportunities
North America is poised to remain the leader in the global blood transfusion diagnostics market. High percentage of voluntary blood donors and implementation of blood transfusion policies for safety and testing for infectious diseases are important growth drivers. The North American market is anticipated to expand at a positive CAGR of 6.4%, capturing over three-tenths of the overall market.
Asia-Pacific is anticipated to grow the fastest, registering a staggering CAGR of 7.0%, capturing greater than two-fifths of the global blood transfusion diagnostics market. This is attributed to high prevalence of TTIs in low-income countries, resulting in greater demand for disease-screening procedures. Moreover, there is a steady increase in the number of blood donation centers and blood donors. There is also an augmented demand for pre-transfusion testing.
Access our latest regional insights on the global blood transfusion diagnostics market, by requesting for a report sample here
Technological Insights: Plasma Fractionation Key Technological Development of Market Players
The global blood transfusion diagnostics market is semi-consolidated, consisting of the following prominent market players: Grifols S.A., Bio-Rad Laboratories, Inc., Immucor, Inc., CSL Ltd., Abbott Laboratories, and DiaSorin S.p.A. These market players concentrate on introducing technological advancements in testing procedures. An example of such technological development is plasma fractionation.
CSL Ltd., is a major player in the plasma fractionation industry. The company collected an estimated 9 million liters of plasma in 2016. In this technique, various components such as immunoglobulins, albumin and other proteins are extracted for several treatment procedures.
Likewise, Grifols S.A also specializes in plasma fractionation techniques. It manufactures plasma derived products for treating various conditions, such as coagulation disorders, pulmonary disorders, immunodeficiencies and shock and trauma. Its products include the BloodChip multiplex blood group genotyping kit based on Luminex technology for the main allelic variants of red blood cells and human platelet antigens.
COVID-19 Market Insights:
COVID-19 is presently the biggest threat to the health and well-being of citizens across the world. Although there is a dearth of specific antiviral agents for its treatment, feasibility studies are underway to determine possible cures. For example, research is being conducted on convalescent plasma transfusion (CP) and its potential to rescue severely ill patients. Results from 10 severe patients showed that one dose of 200 milliliters of CP could significantly increase or maintain neutralizing antibodies at high levels. CP therapy is a classic adaptive immunotherapy which has been applied for over a century. The therapy was also used to treat SARS, MERS and the H1N1 epidemic in 2009 with satisfactory results. Banking on these trends, medical practitioners anticipate to contain the COVID-19 pandemic as well.
The COVID-19 virus especially presents potent challenges to patients with hemoglobin disorders. Though there is no direct link between respiratory conditions and hemoglobin disorders, complications involving the heart, lungs and the immune system, may be present in these patients. A viral infection can only compound the complications. In addition, these patients may be splenectomised and sickle cell patients may be functionally asplenic. Therefore, taking preventive measures for such patients is a major responsibility of medical caregivers. Key market players, notably CSL Behring, are undertaking unprecedented research to develop a potential plasma therapy to treat COVID-19. CSL is part of an alliance developing one, unbranded anti-SARS-CoV-2 polyclonal hyperimmune immunoglobin medicine. The alliance also seeks to support national governments in their efforts to fight the current pandemic.
The global blood transfusion diagnostics market is poised to grow positively during the forecast period. Expansion of the market is based on increasing number of surgical procedures for testing of chronic ailments. Research and development of convalescent plasma (CP) transfusion techniques to boost immunity of patients in the wake of the COVID-19 pandemic is also anticipated to boost market prospects.
Global Blood Transfusion Diagnostics Market: Scope of the Report:
The recent global blood transfusion diagnostics market report by Fact.MR offers a 5-year forecast from 2020 to 2025. The report elaborates on the key drivers, restraints, opportunities and threats to the expansion of the global blood transfusion diagnostics market. A detailed segmental analysis, based on product type, application and end-user, has been provided in the report.
Regional analysis in terms of supply chain analysis, business execution and market value analysis provides an in-depth perspective about the future scope of the global blood transfusion diagnostics market. In addition, a separate section on market structure has also been provided. The section provides a detailed analysis of key market players and the strategies for expansion in the blood transfusion diagnostics market.
Blood Transfusion Diagnostics Market- Scope of the Report
The recent study by Fact.MR on blood transfusion diagnostics market offers a 5-year forecast between 2020 and 2025. The study analyzes crucial trends that are currently determining the growth of blood transfusion diagnostics market. This report explicates on vital dynamics such as the drivers, restraints and opportunities for key market players along with key stakeholders as well as emerging players associated with the provision of blood transfusion diagnostics. The study also provides dynamics responsible for influencing future status of the blood transfusion diagnostics market over the forecast period.
A detailed assessment of blood transfusion diagnostics market value chain analysis, business execution, and supply chain analysis across the regional markets has been covered in the report. A list of prominent companies operating in the blood transfusion diagnostics market along with their product portfolio enhances the reliability of this comprehensive research study.
Blood Transfusion Diagnostics Market: Report Summary
The study offers a comprehensive analysis on diverse features including production capacities, demand, product developments, revenue generation and sales in blood transfusion diagnostics market across the globe.
A comprehensive estimate of blood transfusion diagnostics market has been provided through an optimistic as well as a conservative scenario, taking into account the sales of blood transfusion diagnostics market during the forecast period. Price point comparison by region with global average price is also considered in the study.
Blood Transfusion Diagnostics: Market Segmentation
Fact.MR has studied the blood transfusion diagnostics market with detailed segmentation on the basis of product type, application, end-user and geography.
Kits & Reagents
Molecular Disease Screening
Serological Disease Screening
Plasma Fractionation Companies
Middle East & Africa (MEA)
“This taxonomy prepared is confidential and intended exclusively for the individual or entity with whom it is being shared. Reading, disseminating, distributing, or copying this to any party other than addressee(s) is unauthorized and prohibited.”
Blood Transfusion Diagnostics Market: Analysis on Market Size Evaluation
Blood transfusion diagnostics market has been analyzed for each market segment, in terms of value (US$ Mn).
Market estimates at global and regional levels for blood transfusion diagnostics is available in terms of “US$ Mn” for value. A Y-o-Y growth contrast on prominent blood transfusion diagnostics market segments, along with market attractiveness evaluation, has been incorporated in the report.
Blood Transfusion Diagnostics Market: Inspected Assessment on Regional Segments
Key sections have been elaborated in the blood transfusion diagnostics report, which have helped deliver projection on the regional markets. These chapters include the regional macros (economic, and business environment outlook), which are expected to have a momentous influence on the growth of the blood transfusion diagnostics market during the forecast period.
Country-specific valuation on demand for blood transfusion diagnostics has been offered for each regional market, along with the market scope estimate and forecast, price index, and impact analysis of dynamics of prominence in regions and countries. For all regional markets, Y-o-Y growth estimates have also been incorporated in the report.
Detailed breakup in terms of value for emerging countries has also been included in the report.
Blood Transfusion Diagnostics Market: In-Depth Analysis on Competitive Landscape
The report sheds light on the leading providers of blood transfusion diagnostics along with their detailed profiles. Essential and up-to-date data information related to the market performers, who are principally engaged in the production of blood transfusion diagnostics, has been brought with the help of a detailed dashboard view. Market share analysis and comparison of prominent players provided in the report permits the report readers to take preemptive steps in advancing their businesses.
Company profiles have been included in the report, which includes essentials such as product portfolio, key strategies along with all-inclusive SWOT analysis on each player. Company presence is mapped and presented through the matrix for all the prominent players thus providing the readers with actionable insights, which helps in thoughtfully presenting market status, and predicting the competition level in the blood transfusion diagnostics market. Prominent manufacturers with established market presence in global blood transfusion diagnostics market are Grifols S.A., Bio-Rad Laboratories, Inc., Immucor, Inc., Abbott Laboratories, and DiaSorin S.p.A.
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Blood Transfusion Diagnostics Market
4. Market Overview
4.1.1. Product Type Definition
4.1.2. Industry Evolution / Developments
4.3. Market Dynamics
4.4. Global Blood Transfusion Diagnostics Market Analysis and Forecasts, 2020–2025
4.4.1. Market Revenue Projections (US$ Mn)
4.5. Porter’s Five Force Analysis
5. Spend For Plasma Testing For Infectious Diseases (US$ Mn), by Plasma Fractionation Companies, 2015
6. Global Blood Transfusion Diagnostics Market Analysis and Forecasts, by Product Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Product Type, 2020–2025
6.3.2. Kits & Reagents
6.4. Market Attractiveness, by Product Type
7. Global Blood Transfusion Diagnostics Market Analysis and Forecasts, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2020–2025
7.3.1. Blood Grouping
7.3.2. Disease Screening
220.127.116.11. Serological Disease Screening
18.104.22.168. Molecular Disease Screening
7.4. Market Attractiveness, by Application
8. Global Blood Transfusion Diagnostics Market Analysis and Forecasts, by End-user
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by End-user, 2020–2025
8.3.2. Blood Banks
8.3.3. Diagnostic Laboratories
8.3.4. Plasma Fractionation Companies
8.4. Market Attractiveness, by End-user
9. Global Blood Transfusion Diagnostics Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region
10. North America Blood Transfusion Diagnostics Market Analysis and Forecast
10.1.1. Key Findings
10.2. Market Value Forecast, by Product Type, 2020–2025
10.2.2. Kits & Reagents
10.3. Market Value Forecast, by Application, 2020–2025
10.3.1. Blood Grouping
10.3.2. Disease Screening
10.3.2.1. Serological Disease Screening
10.3.2.2. Molecular Disease Screening
10.4. Market Value Forecast, by End-user, 2020–2025
10.4.2. Blood Banks
10.4.3. Diagnostic Laboratories
10.4.4. Plasma Fractionation Companies
10.5. Market Value Forecast, by Country, 2020–2025
10.6. Market Attractiveness Analysis
10.6.1. By Product Type
10.6.2. By Application
10.6.3. By End-user
10.6.4. By Country
11. Europe Blood Transfusion Diagnostics Market Analysis and Forecast
11.1.1. Key Findings
11.2. Market Value Forecast, by Product Type, 2020–2025
11.2.2. Kits & Reagents
11.3. Market Value Forecast, by Application, 2020–2025
11.3.1. Blood Grouping
11.3.2. Disease Screening
22.214.171.124. Serological Disease Screening
126.96.36.199. Molecular Disease Screening
11.4. Market Value Forecast, by End-user, 2020–2025
11.4.2. Blood Banks
11.4.3. Diagnostic Laboratories
11.4.4. Plasma Fractionation Companies
11.5. Market Value Forecast, by Country/Sub-region, 2020–2025
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Product Type
11.6.2. By Application
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Blood Transfusion Diagnostics Market Analysis and Forecast
12.1.1. Key Findings
12.2. Market Value Forecast, by Product Type, 2020–2025
12.2.2. Kits & Reagents
12.3. Market Value Forecast, by Application, 2020–2025
12.3.1. Blood Grouping
12.3.2. Disease Screening
188.8.131.52. Serological Disease Screening
184.108.40.206. Molecular Disease Screening
12.4. Market Value Forecast, by End-user, 2020–2025
12.4.2. Blood Banks
12.4.3. Diagnostic Laboratories
12.4.4. Plasma Fractionation Companies
12.5. Market Value Forecast, by Country/Sub-region, 2020–2025
12.5.4. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Product Type
12.6.2. By Application
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Blood Transfusion Diagnostics Market Analysis and Forecast
13.1.1. Key Findings
13.2. Market Value Forecast, by Product Type, 2020–2025
13.2.2. Kits & Reagents
13.3. Market Value Forecast, by Application, 2020–2025
13.3.1. Blood Grouping
13.3.2. Disease Screening
220.127.116.11. Serological Disease Screening
18.104.22.168. Molecular Disease Screening
13.4. Market Value Forecast, by End-user, 2020–2025
13.4.2. Blood Banks
13.4.3. Diagnostic Laboratories
13.4.4. Plasma Fractionation Companies
13.5. Market Value Forecast, by Country/Sub-region, 2020–2025
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Product Type
13.6.2. By Application
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Blood Transfusion Diagnostics Market Analysis and Forecast
14.1.1. Key Findings
14.2. Market Value Forecast, by Product Type, 2020–2025
14.2.2. Kits & Reagents
14.3. Market Value Forecast, by Application, 2020–2025
14.3.1. Blood Grouping
14.3.2. Disease Screening
22.214.171.124. Serological Disease Screening
126.96.36.199. Molecular Disease Screening
14.4. Market Value Forecast, by End-user, 2020–2025
14.4.2. Blood Banks
14.4.3. Diagnostic Laboratories
14.4.4. Plasma Fractionation Companies
14.5. Market Value Forecast, by Country/Sub-region, 2020–2025
14.5.1. Saudi Arabia
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Product Type
14.6.2. By Application
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Company Profiles
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company, 2020 (estimated)
15.3. Company Profiles
15.3.1. Grifols S.A.
188.8.131.52. Company Details
184.108.40.206. Business Overview
220.127.116.11. Financial Overview
18.104.22.168. Strategic Overview
22.214.171.124. SWOT Analysis
15.3.2. Immucor, Inc.
126.96.36.199. Company Details
188.8.131.52. Business Overview
184.108.40.206. Financial Overview
220.127.116.11. Strategic Overview
18.104.22.168. SWOT Analysis
15.3.3. Ortho Clinical Diagnostics
22.214.171.124. Company Details
126.96.36.199. Business Overview
188.8.131.52. Financial Overview
184.108.40.206. Strategic Overview
220.127.116.11. SWOT Analysis
18.104.22.168. Company Details
22.214.171.124. Business Overview
126.96.36.199. Financial Overview
188.8.131.52. Strategic Overview
184.108.40.206. SWOT Analysis
15.3.5. Bio-Rad Laboratories, Inc.
220.127.116.11. Company Details
18.104.22.168. Business Overview
22.214.171.124. Financial Overview
126.96.36.199. Strategic Overview
188.8.131.52. SWOT Analysis
15.3.6. F. Hoffman-La Roche Ltd.
184.108.40.206. Company Details
220.127.116.11. Business Overview
18.104.22.168. Financial Overview
22.214.171.124. Strategic Overview
126.96.36.199. SWOT Analysis
15.3.7. QUOTIENT LIMITED
188.8.131.52. Company Details
184.108.40.206. Business Overview
220.127.116.11. Financial Overview
18.104.22.168. Strategic Overview
22.214.171.124. SWOT Analysis
15.3.8. BAG Healthcare GmBH
126.96.36.199. Company Details
188.8.131.52. Business Overview
184.108.40.206. Financial Overview
220.127.116.11. Strategic Overview
18.104.22.168. SWOT Analysis
15.3.9. DiaSorin S.p.A.
22.214.171.124. Company Details
126.96.36.199. Business Overview
188.8.131.52. Financial Overview
184.108.40.206. Strategic Overview
220.127.116.11. SWOT Analysis
15.3.10. Hologic, Inc.
18.104.22.168. Company Details
22.214.171.124. Business Overview
126.96.36.199. Financial Overview
188.8.131.52. Strategic Overview
184.108.40.206. SWOT Analysis
Fact.MR offers custom research services that help clients to get specific research solutions